Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Virtus LifeSci Biotech Clinical Trials ETF(BBC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BBC
10/23/2026: BBC (1-star) is currently NOT-A-BUY. Pass it for now.
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) provides targeted exposure to biotechnology companies in the clinical trial phase, excluding large, commercial-stage pharmaceutical firms. Its primary strength lies in its thematic purity, offering a concentrated play on early-stage innovation that is often diluted in broader sector ETFs. It is best utilized as a satellite holding for investors seeking high growth potential who understand the significant risks of clinical trial failures. Investors should monitor FDA news, industry M&A trends, and interest rates, as these are the primary catalysts and risks. Due to its niche focus, it is more suitable for sophisticated growth-oriented investors rather than those seeking diversification or low-volatility income.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets companies with high growth potential centered on drug development breakthroughs. |
| Momentum investor | Strong fit while signal remains positive | Clinical trial results can create strong price momentum, though this is conditional on favorable news cycles. |
| Value investor | Weak fit | The underlying assets are typically speculative and lack traditional value metrics like consistent earnings. |
| Dividend/Income investor | Weak fit | Clinical-stage companies prioritize research spending over returning capital via dividends. |
| Low-risk investor | Weak fit | The inherent volatility of clinical-stage biotech makes this unsuitable for conservative portfolios. |
Investor Profile
Ideal Investor Profile
The ideal investor is a sophisticated individual or institutional participant with a high risk tolerance, who is specifically looking to express a bullish view on biotechnology innovation.
Suitability
It is best suited for long-term thematic investors who can withstand significant volatility and for active traders looking to hedge or position for sector-specific news events.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Clinical outcomes cause frequent and extreme price fluctuations. |
| Market risk | Medium / high | The biotech sector is sensitive to macroeconomic shifts and changes in risk appetite. |
| Concentration | High | The fund is highly concentrated in a single, high-risk industry. |
| Tracking/expense | Medium | The expense ratio is higher than broad market alternatives. |
| Liquidity | Medium / high | Low trading volume may make it difficult to enter or exit positions without impacting the price. |
| Business/sector quality | High | Many holdings lack commercial products and depend entirely on future regulatory and clinical success. |
Risk Analysis
Volatility
BBC is characterized by high volatility, driven by the binary nature of clinical trial results and the speculative nature of its holdings.
Market Risk
The fund carries significant idiosyncratic and sector risk, where the success of the ETF depends heavily on the regulatory and clinical success of its individual components.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Industry | Biotechnology (Clinical Stage) | 98.5 | This provides concentrated exposure to early and mid-stage biotech firms whose value is driven by drug development outcomes. |
| Cash/collateral | Cash and Cash Equivalents | 1.5 | Minor liquidity reserves are held to facilitate daily fund operations and rebalancing. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type ETF | Historic Profit 104.79% | Avg. Invested days 58 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.